Cargando…
Erratum to: Establishing medical plausibility in the context of orphan medicines designation in the European Union
Autores principales: | Tsigkos, Stelios, Mariz, Segundo, Llinares, Jordi, Fregonese, Laura, Aarum, Stiina, Naumann-Winter, Frauke, Westermark, Kerstin, Sepodes, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596420/ https://www.ncbi.nlm.nih.gov/pubmed/26444545 http://dx.doi.org/10.1186/s13023-015-0309-7 |
Ejemplares similares
-
Establishing medical plausibility in the context of orphan medicines designation in the European Union
por: Tsigkos, Stelios, et al.
Publicado: (2014) -
Use of biomarkers in the context of orphan medicines designation in the European Union
por: Tsigkos, Stelios, et al.
Publicado: (2014) -
Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union
por: Polsinelli, Benedetta, et al.
Publicado: (2017) -
Regulatory Standards in Orphan Medicinal Product Designation in the EU
por: Tsigkos, Stelios, et al.
Publicado: (2021) -
Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit–The EU Regulator's Perspective
por: Sheean, Maria E., et al.
Publicado: (2021)